Found: 149
Select item for more details and to access through your institution.
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
- Published in:
- Archives of Dermatological Research, 2024, v. 316, n. 7, p. 1, doi. 10.1007/s00403-024-03122-w
- By:
- Publication type:
- Article
733 - Nemolizumab elicits fast itch response in atopic dermatitis within 2 days: a post hoc analysis of ARCADIA 1 and 2 data.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.106
- By:
- Publication type:
- Article
638 - Long-term safety and efficacy of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis: a 52-week, phase 3, open-label extension trial.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.019
- By:
- Publication type:
- Article
661 - Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b trial (STREAM-AD).
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.039
- By:
- Publication type:
- Article
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2235, doi. 10.1007/s13555-024-01224-x
- By:
- Publication type:
- Article
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 8, p. 1543, doi. 10.1111/jdv.19925
- By:
- Publication type:
- Article
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 4, p. 669, doi. 10.1007/s40257-024-00855-2
- By:
- Publication type:
- Article
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
- Published in:
- Rheumatology & Therapy, 2024, v. 11, n. 3, p. 617, doi. 10.1007/s40744-024-00654-5
- By:
- Publication type:
- Article
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
- Published in:
- Rheumatology & Therapy, 2024, v. 11, n. 3, p. 633, doi. 10.1007/s40744-024-00657-2
- By:
- Publication type:
- Article
Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
- Published in:
- Arthritis Research & Therapy, 2024, v. 26, p. 1, doi. 10.1186/s13075-023-03257-7
- By:
- Publication type:
- Article
Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii8, doi. 10.1093/bjd/ljad498.010
- By:
- Publication type:
- Article
Tapinarof cream 1% once daily: significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii17, doi. 10.1093/bjd/ljad498.021
- By:
- Publication type:
- Article
Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD).
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii24, doi. 10.1093/bjd/ljad498.028
- By:
- Publication type:
- Article
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 2, p. 204, doi. 10.1001/jamadermatol.2023.5058
- By:
- Publication type:
- Article
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
- Published in:
- BioDrugs, 2024, v. 38, n. 1, p. 121, doi. 10.1007/s40259-023-00630-5
- By:
- Publication type:
- Article
Upadacitinib treatment withdrawal and retreatment in patients with moderate‐to‐severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 12, p. 2558, doi. 10.1111/jdv.19391
- By:
- Publication type:
- Article
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 4, p. 392, doi. 10.1093/bjd/ljad182
- By:
- Publication type:
- Article
Abrocitinib efficacy and safety in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 10, p. 2056, doi. 10.1111/jdv.19280
- By:
- Publication type:
- Article
Guselkumab for the treatment of patients with moderate‐to‐severe hidradenitis suppurativa: A phase 2 randomized study.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 10, p. 2098, doi. 10.1111/jdv.19252
- By:
- Publication type:
- Article
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. 132, doi. 10.1093/bjd/ljad081
- By:
- Publication type:
- Article
388 Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: assessment of pruritus.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.014
- By:
- Publication type:
- Article
390 Efficacy and safety of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2).
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.016
- By:
- Publication type:
- Article
Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 6, p. 810, doi. 10.1093/bjd/ljad060
- By:
- Publication type:
- Article
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study.
- Published in:
- Rheumatology, 2023, v. 62, n. 6, p. 2113, doi. 10.1093/rheumatology/keac607
- By:
- Publication type:
- Article
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.
- Published in:
- Rheumatology, 2023, v. 62, n. 6, p. 2122, doi. 10.1093/rheumatology/keac605
- By:
- Publication type:
- Article
Triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate-to-severe acne in children and adolescents: Randomized phase 2 study.
- Published in:
- Pediatric Dermatology, 2023, v. 40, n. 3, p. 452, doi. 10.1111/pde.15283
- By:
- Publication type:
- Article
Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 4, p. 867, doi. 10.1007/s13555-023-00905-3
- By:
- Publication type:
- Article
Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 2, p. 305, doi. 10.1007/s40257-022-00739-3
- By:
- Publication type:
- Article
Sustained Effectiveness of Secukinumab Across Different Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis from the PURE Registry.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 2, p. 535, doi. 10.1007/s13555-022-00870-3
- By:
- Publication type:
- Article
Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.
- Published in:
- Rheumatology, 2023, v. 62, n. 2, p. 629, doi. 10.1093/rheumatology/keac342
- By:
- Publication type:
- Article
Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 1, p. 269, doi. 10.1007/s13555-022-00849-0
- By:
- Publication type:
- Article
Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice Guidelines.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 1, p. 137, doi. 10.1111/jdv.18571
- By:
- Publication type:
- Article
Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials*.
- Published in:
- British Journal of Dermatology, 2022, v. 187, n. 6, p. 888, doi. 10.1111/bjd.21867
- By:
- Publication type:
- Article
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 12, p. 2731, doi. 10.1007/s13555-022-00822-x
- By:
- Publication type:
- Article
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial.
- Published in:
- Rheumatology & Therapy, 2022, v. 9, n. 5, p. 1361, doi. 10.1007/s40744-022-00474-5
- By:
- Publication type:
- Article
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
- Published in:
- JAMA: Journal of the American Medical Association, 2022, v. 328, n. 11, p. 1073, doi. 10.1001/jama.2022.15632
- By:
- Publication type:
- Article
Management of Atopic Dermatitis in Adults in Saudi Arabia: Consensus Recommendations from the Dermatological Expert Group.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2022, v. 15, p. 1435, doi. 10.2147/CCID.S357178
- By:
- Publication type:
- Article
The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials.
- Published in:
- British Journal of Dermatology, 2022, v. 186, n. 6, p. 1047, doi. 10.1111/bjd.21015
- By:
- Publication type:
- Article
Safety of Janus kinase (JAK) inhibitors in the short‐term treatment of atopic dermatitis.
- Published in:
- International Journal of Dermatology, 2022, v. 61, n. 6, p. 746, doi. 10.1111/ijd.15853
- By:
- Publication type:
- Article
Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 5, p. 1073, doi. 10.1007/s13555-022-00722-0
- By:
- Publication type:
- Article
Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Population pharmacokinetic and exposure–efficacy analysis of ixekizumab in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS).
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 3, p. 1074, doi. 10.1111/bcp.15034
- By:
- Publication type:
- Article
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 2, p. 495, doi. 10.1007/s13555-021-00649-y
- By:
- Publication type:
- Article
Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis.
- Published in:
- Acta Dermato-Venereologica, 2022, v. 102, p. 1, doi. 10.2340/actadv.v102.1984
- By:
- Publication type:
- Article
Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 253, doi. 10.1007/s13555-021-00642-5
- By:
- Publication type:
- Article
Could it be gluten? Additional skin conditions associated with celiac disease.
- Published in:
- International Journal of Dermatology, 2022, v. 61, n. 1, p. 33, doi. 10.1111/ijd.15750
- By:
- Publication type:
- Article